Rubicon Research Limited is pleased to announce walk-in interviews for the positions of Senior Officer/Officer and Executive in Technology Transfer at our Pithampur facility. We are seeking candidates with 2 to 5 years of experience for the Officer/Senior Officer roles and 5 to 8 years for the Executive position. Ideal candidates should possess a B.Pharm or M.Pharm degree, preferably in Pharmaceutics, and have a background in pharmaceutical formulations, specifically solid orals (OSD). The interviews will take place on November 4, 2026, from 10:00 AM to 3:00 PM at our location in Pithampur, District Dhar, MP.
Vacancy details
Department: Technology Transfer
Role:
🔹 Officer / Sr. Officer: 2–5 Years
🔹 Executive: 5–8 Years
Qualification: B.Pharm / M.Pharm (Pharmaceutics preferred)
Experience: Pharmaceutical Formulations – Solid Orals (OSD)
Walk-in interview details
Date of interview: 04th November 2026
Time: 10:00 AM – 3:00 PM
Venue: Rubicon Research Limited, A-17, Phase 2, SEZ, Pithampur, District Dhar, Madhya Pradesh – 454775.
Candidates with experience in Technology Transfer, Product Development, Scale-up and Validation are encouraged to attend.
Please share this opportunity with relevant professionals in your network!
About Rubicon Research Limited
Rubicon Research Pvt. Ltd., now Rubicon Research Limited, is a Mumbai-based, R&D-driven pharmaceutical formulations company founded in 1999. Started as a contract formulation development provider, the company operationalized its oral-solids manufacturing facility at Ambernath, Maharashtra in 2011 and since 2012 has focused on developing, manufacturing and commercializing its own branded specialty and generic prescription products, predominantly for the highly regulated US market. With its principal R&D centre in Thane, India and a development centre for inhalation and nasal products in Ontario, Canada, and two USFDA-inspected, cGMP-compliant manufacturing facilities in Maharashtra, Rubicon has a portfolio of 55+ commercialized products in the US across 69 active NDAs and ANDAs – including oral capsules, tablets, liquids, suspensions and syrups, ophthalmic drops, delayed and extended-release tablets, and drug-device combinations like nasal sprays.
